Score Overview
Explore the 2021 public Archive ranking →
Where Ligand Pharmaceuticals Incorporated has ranked, year by year
Showing 10 years ranking history by HDB Score.
Has not reached the top 50 on HDB Score in any year we have ranked.
- LGND
2005: 80.1% · 2021: 29.5% · free through 2021 · longest runs
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-09-28 | $ 314.10 | — |
1 Year2025-09-26 | $ 169.72 | 85.07% |
5 Years2021-09-28 | $ 86.12 | 264.72% |
10 Years2016-09-28 | $ 63.91 | 391.51% |
20 Years2006-09-28 | $ 25.54 | 12x |
30 Years1996-09-27 | $ 36.19 | 8x |
All Time1992-11-18 | $ 31.39 | 10x |
| Period | Last Price2026-09-28 | 1 Year2025-09-26 | 5 Years2021-09-28 | 10 Years2016-09-28 | 20 Years2006-09-28 | 30 Years1996-09-27 | All Time1992-11-18 |
|---|---|---|---|---|---|---|---|
| Price | $ 314.10 | $ 169.72 | $ 86.12 | $ 63.91 | $ 25.54 | $ 36.19 | $ 31.39 |
| Return | — | 85.07% | 264.72% | 391.51% | 12x | 8x | 10x |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
Reported in USD
| Year | |||
|---|---|---|---|
| TTM | $ 290M | $ 197M | $ 1.35B |
| 2025 | $ 268M | $ 124M | $ 733M |
| 2024 | $ 167M | -$ 4M | $ 256M |
| 2023 | $ 131M | $ 52M | $ 170M |
| 2022 | $ 196M | -$ 33M | $ 211M |
| 2021 | $ 241M | $ 57M | $ 341M |
| 2020 | $ 163M | -$ 2M | $ 411M |
| 2019 | $ 120M | $ 629M | $ 1.06B |
| 2018 | $ 251M | $ 143M | $ 764M |
| 2017 | $ 141M | $ 12M | $ 201M |
| 2016 | $ 108M | -$ 1M | $ 141M |
| 2015 | $ 71M | $ 257M | $ 200M |
| 2014 | $ 64M | $ 12M | $ 167M |
| 2013 | $ 48M | $ 11M | $ 15M |
| 2012 | $ 31M | -$ 527K | $ 12M |
| 2011 | $ 30M | $ 10M | $ 17M |
| 2010 | $ 23M | -$ 12M | $ 22M |
| 2009 | $ 38M | -$ 1M | $ 53M |
| 2008 | $ 27M | -$ 98M | $ 80M |
| 2007 | $ 12M | $ 281M | $ 94M |
| 2006 | $ 140M | -$ 31M | $ 171M |
| 2005 | $ 176M | -$ 36M | $ 86M |
| 2004 | $ 163M | -$ 45M | |
| 2003 | $ 141M | -$ 37M | $ 99M |
| 2002 | $ 96M | -$ 32M | $ 64M |
| 2001 | $ 76M | -$ 42M | $ 37M |
| 2000 | $ 48M | -$ 72M | $ 23M |
| 1999 | $ 40M | -$ 74M | $ 47M |
| 1998 | $ 17M | -$ 117M | $ 32M |
| 1997 | $ 51M | -$ 100M | $ 62M |
| 1996 | $ 36M | -$ 37M | $ 34M |
| 1995 | $ 24M | -$ 64M | $ 16M |
| 1994 | $ 13M | -$ 27M | $ 7M |
Ligand Pharmaceuticals Incorporated fundamental performance
Between 2020 and 2025, revenue grew from $ 163M to $ 268M and net income went from -$ 2M to $ 124M. Revenue increased in 3 of those 5 years; net income in 3.
Between 2015 and 2025, revenue grew from $ 71M to $ 268M and net income declined from $ 257M to $ 124M. Revenue increased in 7 of those 10 years; net income in 7.
Ligand Pharmaceuticals Incorporated currently holds a 20-year HDB Score of 5.5 out of 10. How the HDB Score is calculated.
Membership
Continue LGND’s history
The public Archive runs through 2021. Membership adds recent and current rankings.
- Recent and current rankings across 3,816 companies
- Compare companies with the latest data
- Track your research shortlist in a portfolio
